Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Psilocybin (drug) Clear all
Active, not recruiting Phase 2 Interventional

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

NCT07336238
View directory record Official record
Conditions
Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Psychotherapy, Psilocybin, Survey Administration
Behavioral · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Psilocybin for Opioid Use Disorder (OUD)

NCT06796062
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Albuquerque, New Mexico • Brooklyn, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

NCT06367738
View directory record Official record
Conditions
Aging
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Psilocybin in Cancer Pain Study

NCT06001749
View directory record Official record
Conditions
Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Interventions
Psilocybin
Drug
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

NCT07216404
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Unipolar Depression
Interventions
Biospecimen Collection, Counseling, Interview, Psilocybin, Survey Administration
Procedure · Other · Drug
Lead sponsor
Alan Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Not yet recruiting Phase 2 Interventional

Group PACBT for Depression

NCT07566104
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
Interventions
Psilocybin (drug), Group Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

NCT05265546
View directory record Official record
Conditions
Perception Disorders
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

NCT06349083
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin, Inactive Placebo, Supportive therapy sessions
Drug · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT03775200
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
La Jolla, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 3 Interventional

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

NCT07226232
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

NCT05220410
View directory record Official record
Conditions
Treatment Resistant Depression, Suicidal Ideation
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 6, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional

Effects of Psilocybin in Concussion Headache

NCT03806985
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Placebo oral capsule, Low Dose Psilocybin, High Dose Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

NCT06902974
View directory record Official record
Conditions
Post Traumatic Stress Disorder, PTSD
Interventions
Psilocybin 25 mg
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Wellcome Leap Psilocybin for OUD

NCT06786325
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 6, 2026, 4:14 PM EDT
Withdrawn Phase 2 Interventional

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

NCT00979693
View directory record Official record
Conditions
Anxiety, Stage IV Melanoma
Interventions
psilocybin
Drug
Lead sponsor
Multidisciplinary Association for Psychedelic Studies
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 6, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Psilocybin Brain Stimulation and Imaging Pilot Study

NCT06835699
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Psilocybin 25 mgs, TMS
Drug · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Optimizing Microdosing and Meditation

NCT06560658
View directory record Official record
Conditions
Meditation, Microdosing
Interventions
Psilocybin, Meditation
Drug · Behavioral
Lead sponsor
National University of Natural Medicine
Other
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

NCT06814522
View directory record Official record
Conditions
Burnout, Burnout, Healthcare Workers
Interventions
Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Real-time Biofeedback
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The RECAP2 Study: Midazolam and Psilocybin

NCT06692192
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Midazolam, Saline
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Early Phase 1 Interventional

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

NCT06656702
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin for Prolonged Grief Disorder

NCT06724289
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Psilocybin 25 mg, Functional Magnetic Resonance Imaging (fMRI)
Drug · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

NCT07818564
View directory record Official record
Conditions
Phase I
Interventions
Psilocybin (Usona Institute), Inactive Placebo (Usona Institute)
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 4:14 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin Administration With 5-HT1a Blockade

NCT07565493
View directory record Official record
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Pindolol, Placebo, Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 4:14 PM EDT